Netherlands-based biotechnology firm MIMETAS has partnered with Roche to develop a new organ-on-a-chip system to support intestinal permeability assessment.
The new system is designed to enable evaluation in perfused three-dimensional (3D) gut tubules in high throughput under exposure to pharmacological compounds. As part of their research, the firms are reported to have grown more than 350 gut tubules under flow to form leak-tight structures.